Is YMTX or EQR a better dividend investment in 2026?

YMTX currently yields 105.82% with a 5% 5-year dividend growth rate. EQR yields 5.87% with 5% growth. The better choice depends on your goal: YMTX offers higher current income.

What is the dividend yield difference between YMTX and EQR?

YMTX has a forward dividend yield of 105.82% ($2.00/share annually). EQR yields 5.87% ($3.47/share annually). The yield gap is 99.95 percentage points.

Home › Compare › YMTX vs EQR

YMTX vs EQR: Dividend Comparison 2026

YMTX yields 105.82% · EQR yields 5.87%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 YMTX wins by $4.88M in total portfolio value

INVESTMENT

TIME HORIZON10 years

YMTX

● Live price

105.82%

Share price

$1.89

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$4.93M

Annual income

$1,723,843.10

Full YMTX calculator →

EQR

● Live price

5.87%

Share price

$59.15

Annual div

$3.47

5Y div CAGR

15.8%

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$47.8K

Annual income

$5,475.61

Full EQR calculator →

Portfolio growth — YMTX vs EQR

📍 YMTX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	YMTX	EQR
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, YMTX + EQR cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

YMTX pays

EQR pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

YMTX

Annual income on $10K today (after 15% tax)

$8,994.71/yr

After 10yr DRIP, annual income (after tax)

$1,465,266.64/yr

EQR

Annual income on $10K today (after 15% tax)

$499.01/yr

After 10yr DRIP, annual income (after tax)

$4,654.27/yr

At 15% tax rate, YMTX beats the other by $1,460,612.37/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of YMTX + EQR for your $10,000?

YMTX: 50%EQR: 50%

100% EQR50/50100% YMTX

Portfolio after 10yr

$2.49M

Annual income

$864,659.35/yr

Blended yield

34.75%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

YMTX

Analyst Ratings

Buy

Consensus: Buy

Altman Z

-21.9

Piotroski

3/9

EQR

Analyst Ratings

Buy

Hold

Sell

Consensus: Hold

Price Target

$70.35

+18.9% upside vs current

Range: $63.00 — $78.50

Altman Z

1.8

Piotroski

7/9

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

YMTX buys

EQR buys

No recent congressional trades found for YMTX or EQR in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricYMTXEQR

Forward yield	105.82% ✓	5.87%
Annual dividend / share	$2.00	$3.47 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	15.8% ✓
Portfolio after 10y	$4.93M	$47.8K ✓
Annual income after 10y	$1,723,843.10 ✓	$5,475.61
Total dividends collected	$4.43M	$23.0K ✓
Payment frequency	quarterly	quarterly
Sector	Stock	REIT
Analyst consensus	Buy	Hold

Year-by-year: YMTX vs EQR ($10,000, DRIP)

Year	YMTX Portfolio	YMTX Income/yr	EQR Portfolio	EQR Income/yr	Gap
1← crossover	$21,282	$10,582.01	$11,380	$679.82	+$9.9K → YMTX
2	$43,819	$21,047.33	$13,014	$837.25	+$30.8K → YMTX
3	$87,387	$40,500.83	$14,961	$1,036.20	+$72.4K → YMTX
4	$168,990	$75,485.74	$17,297	$1,289.22	+$151.7K → YMTX
5	$317,245	$136,425.12	$20,121	$1,613.15	+$297.1K → YMTX
6	$578,807	$239,355.52	$23,561	$2,030.84	+$555.2K → YMTX
7	$1,027,455	$408,130.85	$27,783	$2,573.54	+$999.7K → YMTX
8	$1,776,463	$677,086.81	$33,013	$3,284.39	+$1.74M → YMTX
9	$2,994,908	$1,094,092.83	$39,547	$4,223.51	+$2.96M → YMTX
10	$4,928,395	$1,723,843.10	$47,791	$5,475.61	+$4.88M → YMTX

YMTX vs EQR: Complete Analysis 2026

YMTX — Stock

Yumanity Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of treatments for neurodegenerative diseases caused by protein misfolding. The company focuses on discovering disease-modifying therapies to treat neurodegenerative diseases, including Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, amyotrophic lateral sclerosis, and frontotemporal lobar degeneration. Its lead program is YTX-7739, a novel small molecule that is in Phase I clinical trial for the treatment of Parkinson's disease and related disorders of a-synuclein. The company is also developing YTX-9184, which is in preclinical studies to treat neurological disorders. Yumanity Therapeutics Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Full YMTX Calculator →

EQR — REIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →

📬

Get this YMTX vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

YMTX vs SCHD YMTX vs JEPI YMTX vs O YMTX vs KO YMTX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.